跳至主要内容
临床试验/NCT05288998
NCT05288998进行中(未招募)不适用

Noninvasive Evaluation of the Intrarenal Microvasculature in ADPKD

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2021年11月30日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Mayo Clinic
入组人数
34
试验地点
1
主要终点
Assessment of intrarenal microvascular density in HV and patients with ADPKD

研究概览

简要总结

The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and healthy volunteers.

详细描述

An intact intrarenal microcirculation is vital to preserving normal kidney function, and microvascular dysfunction, damage, and loss are known to contribute to renal function decline. In ADPKD, extensive vascular remodeling has been proposed to play an important role in its progression. However, microvascular analyses in rodents and humans with ADPKD have been performed ex vivo or in vitro and from kidneys removed at the time of renal failure due to the invasive nature and additional limitations of the currently available techniques. A non-invasive and direct method to assess the intrarenal microvasculature is needed to improve early detection and gauge the progression of microvascular alterations and monitor the success of therapeutic approaches.

Current imaging modalities, such as micro-computed tomography, magnetic resonance imaging, and contrast-enhanced ultrasound, have attempted to provide a non-invasive assessment of the intrarenal microvasculature in pre-clinical models of kidney diseases. However, each of these modalities has important limitations when translating into humans, including high cost, requiring long imaging times, using nephrotoxic contrast agents, radiation exposure, low spatial resolution, and poor reproducibility.

Super-resolution ultrasound (SRU) imaging is among the most rapidly advancing imaging techniques introduced to overcome the limitation of the inherent spatial resolution of ultrasound. With the use of non-nephrotoxic contrast microbubbles to break the diffraction limit of ultrasound, and the introduction of ultrasound localization microscopy which utilizes ultrafast frame rate imaging to reconstruct a super-resolved composite image, SRU has provided a paradigm-shifting tool for structural and functional evaluation of tissue microvasculature. However, in vivo, human imaging, and kidney imaging pose significant organ depth challenges (which results in ultrasound signals with lower signal-to-noise ratio) and physiologic and operator-induced motion (which reduces the available data accumulation time). Our team recently implemented advanced filtering and microbubble localization and tracking techniques to overcome these limitations, which extract only microbubble signals and reliably pinpoint the center of each microbubble from the extracted signals.

The investigators' broad objective is to deploy and evaluate the use of SRU imaging coupled with advanced post-processing techniques to assess the intrarenal microvasculature in patients with early ADPKD and healthy volunteers.

Participants in this study will have a renal ultrasound to determine intrarenal microvascular parameters, and an abdominal MRI to determine the patient's total kidney volume (TKV), and additional vascular parameters. In addition, participants will have a blood and a urine sample collected to determine biomarkers of endothelial function and injury.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • (Patients with ADPKD):
  • Male and female subjects 18 - 40 years of age, inclusive
  • Previous diagnosis of ADPKD (based on Ravine et al. criteria)
  • Class 1 according to imaging classification
  • Estimated GFR> 90 mL/min/m2 (CKD-Epi equation)
  • Ability to provide written, informed consent
  • Inclusion Criteria (Healthy Volunteers):
  • Male and female subjects 18 - 40 years of age, inclusive
  • Estimated GFR> 90 mL/min/m2 (CKD-Epi equation)
  • Ability to provide written, informed consent

排除标准

  • (Patients with ADPKD):
  • Class 2 according to imaging classification
  • A concomitant systemic disease affecting the kidney (e.g., lupus, hepatitis B or C, amyloidosis)
  • Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics).
  • Predicted urine protein excretion in urinalysis >1 g/24 hrs.
  • Subjects having contraindications to or interference with MRI assessments. [For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.].
  • History of hypersensitivity allergic reactions to ultrasound contrast agents
  • High-risk cardiac disease (such as unstable hospital in-patients or ICU patients
  • Patients that are part of an interventional study or are taking tolvaptan
  • Female subjects that are pregnant
  • Exclusion Criteria (Healthy Volunteers):
  • Family and/or personal history of kidney disease
  • Concomitant systemic disease that may affect the kidney
  • Diabetes mellitus
  • Predicted urine protein excretion in >1 g/24 hrs, and or Abnormal urinalysis
  • Pregnant or lactating women
  • Subjects having contraindications to or interference with MRI assessments. [For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.].
  • History of hypersensitivity allergic reactions to ultrasound contrast agents
  • High risk cardiac disease (such as unstable hospital in-patients or ICU patients

研究组 & 干预措施

Patients with a previous diagnosis of ADPKD

Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria

Healthy Volunteers

Subjects without a family or personal history of kidney disease or concomitant systemic disorder that might affect the kidney

结局指标

主要结局

Assessment of intrarenal microvascular density in HV and patients with ADPKD

时间窗: Baseline

Renal vessel density as percentage, determined by SRU.

Assessment of intrarenal microvascular flow speed in HV and patients with ADPKD

时间窗: Baseline

Microvascular flow speed (mm/s), determined by SRU.

Assessment of intrarenal microvascular perfusion in HV and patients with ADPKD

时间窗: Baseline

Intrarenal perfusion (mm/s), determined by SRU.

Assessment of intrarenal tortuosity indices in HV and patients with ADPKD

时间窗: Baseline

Tortuosity indices defined as sum of angles metric (SOAM) (rad/mm), determined by SRU

次要结局

  • Day-to-day variability of intrarenal microvasculature in healthy volunteers(Baseline to 7 days)
  • Inter-sonographer variability of the intrarenal microvasculature(Baseline)
  • Patient-to-patient variability in patients with ADPKD(Baseline)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Maria V. Irazabal Mira

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验